Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 6/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 5/20 | 1.00 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.57 |
| ▸ | ADRA2A | P08913 | 7/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 5/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 5/20 | 0.51 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12355112 | 0.80 | CYP19A1 (0.71) | CYP11B2CYP19A1CYP17A1ADRA2AADRA2B | |
| SCHEMBL13196399 | 0.80 | ADRA2A (0.71) | CYP11B2CYP19A1ADRA2AADRA2BADRA2C | |
| SCHEMBL7943729 | 0.77 | CYP19A1 (1.00) | CYP11B2CYP19A1CYP17A1SMN1; SMN2 | |
| SCHEMBL779556 | 0.76 | ADRA2A (0.64) | CYP11B2CYP19A1ADRA2AADRA2BADRA2C | |
| SCHEMBL18826066 | 0.70 | CYP19A1 (0.54) | CYP11B2CYP19A1ADRA2AADRA2BADRA2C | |
| SCHEMBL18826073 | 0.68 | HRH3 (0.52) | CYP11B2CYP19A1ADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL9529847 | 0.67 | HRH3 (0.50) | CYP11B2CYP19A1ADRA2AADRA2BADRA2C | |
| SCHEMBL27387166 | 0.67 | HTR6 (0.50) | CYP11B2CYP19A1 | |
| SCHEMBL4372076 | 0.66 | KDM1A (0.63) | CYP11B2CYP19A1CYP17A1 | |
| SCHEMBL14653364 | 0.64 | CYP11B2 (0.52) | CYP11B2CYP19A1CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190247-A1 | CYCLOPROPYLCHROMENE DERIVATIVES AS MODULATORS OF THE ALPHA-2C RECEPTOR | SCHERING CORPORATION (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190247-A1 | CYCLOPROPYLCHROMENE DERIVATIVES AS MODULATORS OF THE ALPHA-2C RECEPTOR | SCHERING CORPORATION (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2010017120-A1 | CYCLOPROPYLCHROMENE DERIVATIVES AS MODULATORS OF THE ALPHA-2C RECEPTOR | SCHERING CORPORATION (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190247-A1 | CYCLOPROPYLCHROMENE DERIVATIVES AS MODULATORS OF THE ALPHA-2C RECEPTOR | ADRA2C, ADRB2, ADRA2A | CYP11B2 43/4885CYP19A1 677/4885CYP17A1 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.